I 
116TH CONGRESS 
2D SESSION 
H. R. 9027 
To authorize the Patient-Centered Outcomes Research Institute to fund 
research of the symptoms of COVID–19, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
DECEMBER 18, 2020 
Mr. BEYER introduced the following bill; which was referred to the Committee 
on Energy and Commerce, and in addition to the Committee on Ways 
and Means, for a period to be subsequently determined by the Speaker, 
in each case for consideration of such provisions as fall within the juris-
diction of the committee concerned 
A BILL 
To authorize the Patient-Centered Outcomes Research Insti-
tute to fund research of the symptoms of COVID–19, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘COVID–19 Long 
Haulers Act’’. 
VerDate Sep 11 2014 
02:39 Jan 05, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H9027.IH
H9027
SSpencer on DSK126QN23PROD with BILLS
SEC. 2. AUTHORIZATION TO FUND RESEARCH OF THE 
LONG-TERM SYMPTOMS OF COVID–19 BY THE 
PATIENT-CENTERED OUTCOMES RESEARCH 
INSTITUTE. 
(a) IN GENERAL.—The Patient-Centered Outcomes 
Research Institute under section 1181(b) of the Social Se-
curity Act (42 U.S.C. 1320e(b)) shall fund research de-
scribed in subsection (b). 
(b) RESEARCH DESCRIBED.—For purposes of sub-
section (a), research described in this subsection shall in-
clude— 
(1) prior to creating a patient registry described 
in paragraph (2), survey existing patient registries 
that include individuals experiencing post-acute 
sequelae of COVID–19; 
(2) creating a patient registry for those with 
COVID–19 with information that— 
(A) contains the— 
(i) symptoms that arise while an indi-
vidual is actively infected with COVID–19 
and that resolve while such individual is 
actively infected; 
(ii) symptoms that arise while an indi-
vidual is actively infected with COVID–19 
and that extend after the infection has re-
solved; 
VerDate Sep 11 2014 
02:39 Jan 05, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H9027.IH
H9027
SSpencer on DSK126QN23PROD with BILLS
(iii) symptoms that arise after an in-
dividual is actively infected with COVID– 
19 and that endure and that the clinician 
of such individual has reason to suspect 
were related to the COVID–19 diagnosis; 
(iv) symptoms that arise in an indi-
vidual that may be related to COVID–19 
but a diagnosis of COVID–19 was not ob-
tained and cannot be identified due to a 
lack of antibodies; 
(v) treatments of individuals after pri-
mary diagnosis to COVID–19 and the ef-
fectiveness of such treatments disaggre-
gated by age, gender, and race or eth-
nicity; and 
(vi) any other relevant questions or 
issues related to individuals who experience 
a diagnosis of, treatment for, and manage-
ment of care with COVID–19; 
(B) synthesizes information relating to in-
dividuals experiencing post-acute sequelae of 
COVID–19 identified from the survey described 
in paragraph (1) and information under the pa-
tient registry described in paragraph (2); and 
VerDate Sep 11 2014 
02:39 Jan 05, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H9027.IH
H9027
SSpencer on DSK126QN23PROD with BILLS
(3) outreach and inclusion (as appropriate) in-
dividuals from communities with traditional health 
disparities and inequities. 
(c) REPORT.—Not later than 1 year after the estab-
lishment of the synthesized patient registry described in 
subsection (a)(2), and annually thereafter, the Patient- 
Centered Outcomes Research Institute shall submit data, 
findings, and information with respect to the status of the 
patient registry (including progress, barriers, and issues) 
to Congress and the President. 
(d) AUTHORIZATION OF APPROPRIATIONS.—There is 
hereby authorized $30,000,000 for fiscal year 2021 to 
carry out this section, which shall remain available until 
expended. 
SEC. 3. AUTHORIZATION OF APPROPRIATIONS FOR RE-
SEARCH WITH RESPECT TO INDIVIDUALS EX-
PERIENCING 
POST-ACUTE 
SEQUELAE 
OF 
COVID–19 BY THE NIH. 
(a) IN GENERAL.—The Director of the National In-
stitutes of Health conduct research with respect to individ-
uals experiencing post-acute sequelae of COVID–19. 
(b) AUTHORIZATION OF APPROPRIATIONS.—There is 
hereby authorized $100,000,000 for fiscal year 2021 to 
VerDate Sep 11 2014 
02:39 Jan 05, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H9027.IH
H9027
SSpencer on DSK126QN23PROD with BILLS
carry out this section, which shall remain available until 
expended. 
Æ 
VerDate Sep 11 2014 
02:39 Jan 05, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H9027.IH
H9027
SSpencer on DSK126QN23PROD with BILLS